Madison Asset Management LLC Invests $128.96 Million in Medpace Holdings, Inc. $MEDP

Madison Asset Management LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 243,502 shares of the company’s stock, valued at approximately $128,956,000. Medpace comprises 1.5% of Madison Asset Management LLC’s investment portfolio, making the stock its 16th biggest position. Madison Asset Management LLC owned about 0.87% of Medpace as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in MEDP. BlackRock Inc. bought a new stake in Medpace in the 2nd quarter valued at $1,323,047,000. AQR Capital Management LLC lifted its holdings in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after acquiring an additional 183,645 shares during the period. Finally, Norges Bank bought a new stake in shares of Medpace in the fourth quarter valued at about $102,156,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $608.27 on Thursday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The stock has a market capitalization of $16.98 billion, a P/E ratio of 35.65, a PEG ratio of 2.63 and a beta of 1.15. The stock’s fifty day moving average is $544.34 and its 200 day moving average is $491.59.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Activity

In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president directly owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 67,195 shares of company stock valued at $37,989,998 over the last quarter. 20.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on MEDP shares. Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, Royal Bank Of Canada lifted their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.